#WCLC21: As­traZeneca's EGFR in­hibitor Tagris­so cuts re­lapse, death risks in pa­tients with and with­out pri­or chemother­a­py

As­traZeneca’s Tagris­so has es­tab­lished a strong foothold in non-small cell lung can­cer — the largest sec­tion of the lung can­cer com­mu­ni­ty — with mul­ti­ple ap­provals in the ear­ly set­ting. Those ap­provals in­clude pa­tients with re­moved tu­mors, an in­di­ca­tion where physi­cians have gone back and forth on the use of chemother­a­py.

Now, As­traZeneca may have an an­swer for the chemo de­bate: It doesn’t re­al­ly mat­ter in terms of our drug’s ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER